Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy

Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy

The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients undergoing LASIK or photorefractive keratectomy (PRK).

Inclusion Criteria:

• Males or females > 18 years old
• Mild-moderate symptoms of dry eye prior to surgery
• Scheduled to undergo bilateral LASIK or PRK
• Likely to complete all study visits and able to provide informed consent

Exclusion Criteria:

• Prior use of topical cyclosporine within the last 1 year
• Known contraindications to any study medication or ingredients
• Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.
• Ocular disorders
• Active ocular diseases or uncontrolled systemic disease
• Active ocular allergies